Tactile Systems Technology Inc

Tactile Systems Technology Inc(TCMD)股票分析

$23.640

+0.099 (+0.42%)收盤時

Loading chart…
最高
23.840
開盤
23.560
成交量加權均價
23.65
成交量
130.81K
市值
274.93M
最低
23.480
成交金額
3.09M
企業價值/稅息折舊攤銷前利潤(TTM)
12.47

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.

AI 分析 of Tactile Systems Technology Inc (TCMD)

買進

Tactile Systems Technology Inc is a good buy right now at a current price of $23.64, especially considering its strong revenue growth of 57.60% over the past year and a solid gross margin of 75.50% in Q2 2026. The RSI is at 67.38, indicating bullish momentum, and the forward P/E ratio of 19.12 suggests it is reasonably valued compared to its growth prospects. However, the main risk is the recent decline of 13.72% year-to-date, which reflects market volatility and potential earnings challenges ahead.

分析師評級(6)

上檔空間 +33.97%
買進
6 買進
0 持有
0 賣出
目前: 23.64
最低
28.00
平均
31.67
最高
35.00

BTIG

2026-10-12

目標價

$35

買進

B. Riley

2026-05-07

目標價

$36

買進

BTIG

2026-05-05

目標價

$40

買進

BTIG

2026-02-18

目標價

$38

買進

B. Riley

2026-02-18

目標價

$32

中性

估值指標

Tactile Systems Technology Inc(TCMD)目前預期本益比為 19.12,5 年平均預期本益比為 73.87。

預期本益比

合理
5 年均值 P/E
73.87
目前P/E
19.12
高估
427.37
低估
-279.63

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-7.61
目前EV/EBITDA
12.47
高估
75.67
低估
-90.88

預期股價營收比

合理
5 年均值 P/S
1.22
目前P/S
1.34
高估
1.63
低估
0.81

Alphio AI 對 TCMD 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%TCMD

$12.55

情境價格

基

基準

基準 · 50%TCMD

$12.06

情境價格

悲

悲觀

悲觀 · 25%TCMD

$10.94

情境價格

持有 TCMD 的大戶

F

First Light Asset Management, LLC

+ 持有TCMD

-9.40%

3個月報酬率

事件時間軸

2026-08-10 (ET)

16:30:00

Tactile Medical Q2 Revenue $85.7M Beats Expectations

2026-05-04 (ET)

16:30:00

Tactile Medical Q1 Revenue $75.27M, Exceeds Expectations

16:30:00

Company Updates 2026 Revenue Outlook to $368 Million

2026-03-09 (ET)

08:30:00

Tactile Systems Appoints Andrea Pearson to Board of Directors

2026-02-17 (ET)

17:00:00

Tactile Systems Acquires LymphaTech for $6.8M

資訊

TCMD 常見問題 —— 由 Alphio AI 解答

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tactile Systems Technology Inc is a good buy right now at a current price of $23.64, especially considering its strong revenue growth of 57.60% over the past year and a solid gross margin of 75.50% in Q2 2026. The RSI is at 67.38, indicating bullish momentum, and the forward P/E ratio of 19.12 suggests it is reasonably valued compared to its growth prospects. However, the main risk is the recent decline of 13.72% year-to-date, which reflects market volatility and potential earnings challenges ahead.

6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易